Genmab and AbbVie blood cancer drug combination confirmed to reduce risk of death
智通财经2026/10/06 07:01Show original
Traders expect Genmab's stock price to rise by 5%-7% after the combination blood cancer drug developed in collaboration with AbbVie was proven to reduce mortality risk.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
Traders said that after it was confirmed that the blood cancer drug combination jointly developed by Genmab and AbbVie can reduce the risk of death, Genmab's share price is expected to rise by 5%-7%.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Crypto prices
More
Bitcoin
BTC
$82,991.01
+0.57%
Ethereum
ETH
$2,507.84
+1.02%
Tether USDt
USDT
$0.9991
+0.00%
BNB
BNB
$750.19
+1.23%
XRP
XRP
$1.41
+1.05%
USDC
USDC
$0.9999
+0.00%
Solana
SOL
$110.25
+1.10%
TRON
TRX
$0.3307
-0.36%
Hyperliquid
HYPE
$85.4
+1.69%
Zcash
ZEC
$1,226.25
+1.18%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now